NCT03915938

Brief Summary

This is a clinical trial that intend to determine the effects of S-ketamine on event-related potentials associated with semantic affective pain-processing

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started Jan 2017

Shorter than P25 for phase_2

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 2, 2017

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2017

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

April 12, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 16, 2019

Completed
Last Updated

April 16, 2019

Status Verified

January 1, 2018

Enrollment Period

11 months

First QC Date

April 12, 2019

Last Update Submit

April 15, 2019

Conditions

Keywords

KetamineERPOddball

Outcome Measures

Primary Outcomes (1)

  • AUC of the grand averaged mean differences between ERPs elicited by target and non-target words

    EEG will be recorded during all task time. The main outcome will be the area under de curve (AUC) of the grand averaged mean differences between event-related potencials (ERPs) elicited by target and non-target words at 100-200, 300-500 and 800-900 ms after stimulus presentation for parietal electrophysiological signal (Pz). The ERPs represent the averaged voltage of several trials.

    up to 60 min

Secondary Outcomes (2)

  • Word ratings related to the semantic valence

    up to 60 min

  • Response times (behavioural oddball data)

    up to 60 min

Other Outcomes (2)

  • Subjective euphoria rating

    up to 60 min

  • Subjective sedation rating

    up to 60 min

Study Arms (2)

Group S-Ketamine

EXPERIMENTAL

S-Ketamine will be diluted in normal saline and administrated in a target controlled infusion using an infusion pump to obtain a plasma target of 60 ng/ml according to Domino's model. Infusion will start during the interval between the 3rd and 4th blocks of the task.

Drug: Ketamine

Group Placebo

PLACEBO COMPARATOR

A previously prepared identical solution containing only normal saline will be infused at the same infusion rates of group ketamine.

Drug: Placebo

Interventions

S-ketamine will be administered in precalculated infusion rates to obtain a plasmatic level of 60 ng/ml

Group S-Ketamine

Administered in an identical way than ketamine.

Group Placebo

Eligibility Criteria

Age18 Years - 40 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • male healthy subjects with higher education level

You may not qualify if:

  • do not understand Portuguese language
  • obese patients (BMI \> 27 kg/m2)
  • use of NSAID, steroids, analgesics, anticonvulsant drugs, as well as alpha and beta-blockers
  • score ≥ 13 on Beck II Questionnaire
  • sleep deprivation in the night before evaluation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Schwertner A, Zortea M, Torres FV, Ramalho L, Alves CFDS, Lannig G, Torres ILS, Fregni F, Gauer G, Caumo W. S-Ketamine's Effect Changes the Cortical Electrophysiological Activity Related to Semantic Affective Dimension of Pain: A Placebo- Controlled Study in Healthy Male Individuals. Front Neurosci. 2019 Sep 13;13:959. doi: 10.3389/fnins.2019.00959. eCollection 2019.

MeSH Terms

Conditions

Acute PainChronic PainSchizophrenia

Interventions

Ketamine

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsSchizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Intervention Hierarchy (Ancestors)

CyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsOrganic Chemicals

Study Officials

  • Wolnei Caumo, MD, PhD

    Hospital de Clínicas de Porto Alegre

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 12, 2019

First Posted

April 16, 2019

Study Start

January 2, 2017

Primary Completion

November 30, 2017

Study Completion

November 30, 2017

Last Updated

April 16, 2019

Record last verified: 2018-01